Welcome to our dedicated page for SHOULDER INNOVATIONS SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
Gilde Healthcare Holding B.V., a 10% owner of Shoulder Innovations, reported indirect open-market sales totaling 9,433 common shares. On August 5, 2026 an affiliated entity sold 7,338 shares at a $22.64 weighted-average price from $22.60–$23.00, followed by 2,095 shares at $22.60 on August 6, 2026. The shares are held of record by Cooperatieve Gilde Healthcare V U.A., over which Gilde-related entities have voting and dispositive power.
Shoulder Innovations, Inc. has filed a mixed shelf registration allowing it to offer, from time to time, up to $300,000,000 of securities, including common stock, preferred stock, debt securities, warrants, subscription rights and units, in one or more offerings after effectiveness, with specific terms to be set in prospectus supplements.
The filing also registers up to 8,103,026 shares of common stock for resale by existing selling stockholders; these holders will receive all proceeds from their sales, while the company will receive none. Shoulder Innovations’ common stock trades on the NYSE under “SI,” and 20,761,754 shares of common stock were outstanding as of June 30, 2026. The company is a commercial-stage medical technology business focused on shoulder arthroplasty implant systems and related enabling technologies.
Shoulder Innovations, Inc. reported strong top-line growth for the quarter ended June 30, 2026. Net revenue reached $17,175 thousand, up 56.0% from a year earlier, driven by higher procedure volumes; implant systems sold increased to 2,238 from 1,503. Gross margin improved to 78.3%, reflecting scale benefits and pricing.
Operating loss widened to $10,036 thousand as selling, general and administrative expenses increased 56.3% and research and development 141.2%, supporting commercial expansion and a robotics platform partnership. However, net loss narrowed to $10,153 thousand from $19,196 thousand, mainly because prior-year results included an $11,719 thousand non-cash Series E purchase option fair value charge. Adjusted EBITDA loss improved to $8,023 thousand from $18,073 thousand.
For the first half of 2026, net revenue grew 60.2% to $33,883 thousand, with gross margin of 78.0%. The company ended June with $98,993 thousand in cash, cash equivalents and marketable securities and a new $15,000 thousand term loan plus a $30,000 thousand undrawn revolving credit facility with Stifel Bank.
Shoulder Innovations reported strong second quarter 2026 results, with net revenue of $17.2 million, a 56% increase over the prior-year quarter, and gross margin expanding to 78.3% from 76.2%. Growth was driven by higher implant volumes, more customers and a higher average selling price of $7,674.
The company sold 2,238 implant systems, about 50% more than a year earlier, but continued to invest heavily, lifting selling, general and administrative expenses to $20.1 million and research and development to $3.4 million. Operating loss widened to $10.0 million, while net loss narrowed to $10.2 million and Adjusted EBITDA loss to $8.0 million.
Shoulder Innovations closed two new credit facilities totaling up to $50 million and ended June 30, 2026 with $99.0 million in cash, cash equivalents and marketable securities. On this basis it raised full-year 2026 net revenue guidance to $67–69 million, implying about 42–46% growth over 2025.
FMR LLC and related reporting person Abigail P. Johnson report beneficial ownership of common stock of Shoulder Innovations Inc. FMR LLC reports beneficial ownership of 3,673,960 shares of common stock, representing 17.7% of the class, with 3,655,660 shares subject to sole voting power and 3,673,960 shares subject to sole dispositive power.
Abigail P. Johnson reports beneficial ownership of 3,673,960 shares with sole dispositive power but no sole or shared voting power, reflecting her position as a control person of FMR LLC. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no such person holds more than 5% of the total outstanding common stock.
Gilde Healthcare Holding B.V., a ten percent owner of Shoulder Innovations, reported indirect sales of 110,563 shares of common stock through Cooperatieve Gilde Healthcare V U.A. on August 3–4, 2026 at weighted average prices of $22.71 and $22.77 per share.
Gilde Healthcare Holding B.V., a 10% shareholder of Shoulder Innovations, sold 48,279 shares of common stock on July 30–31, 2026 in indirect open‑market transactions at weighted‑average prices of $23.36 and $22.73 per share, within the disclosed intraday ranges. The shares are held through Coöperatieve Gilde Healthcare V U.A. and related entities, and a Gilde partner disclaims beneficial ownership beyond any pecuniary interest; the trades were not reported under a Rule 10b5‑1 plan.
A selling security holder plans to dispose of 200,000 shares of common stock of the issuer through transactions on the NYSE, with an indicated aggregate market value of $4,850,000.00. The shares are proposed to be sold beginning on 07/29/2026, with 20,738,226 shares of common stock stated as outstanding.
The shares to be sold were acquired in several transactions, including private placements of Series D and Series E convertible preferred stock on 02/10/2023 and 03/06/2025, respectively, which converted into common stock upon the IPO closing on 08/01/2025, with the holding period tacking under Rule 144(d)(3)(ii). An additional 100,000 shares were purchased in the issuer’s registered IPO on 08/01/2025 at $15.00 per share as control securities.
Tansey Casey M reported acquisition or exercise transactions in this Form 4 filing.
Shoulder Innovations, Inc. director and 10% owner Casey M. Tansey reported an equity award and updated holdings. He received a grant of 5,046 restricted stock units (RSUs) of common stock at $0.00 per share, increasing his directly held shares to 52,712 after the award.
The RSUs vest on the earlier of the company’s 2027 annual stockholder meeting or June 26, 2027, with each RSU delivering one common share. Tansey elected to defer settlement of these RSUs until his departure from the Board. Additional common stock is held indirectly through U.S. Venture Partners funds and related Presidio Management Group entities, where Tansey may share voting and dispositive power but beneficial ownership is disclaimed except for any pecuniary interest.
Sidow Kevin K. reported acquisition or exercise transactions in this Form 4 filing.
SHOULDER INNOVATIONS, INC. director Kevin K. Sidow received an equity grant of 5,046 restricted stock units (RSUs), each representing one future share of common stock at no purchase price. These RSUs vest on the earlier of the 2027 annual stockholder meeting or June 26, 2027.
Sidow has voluntarily elected to defer receipt of the underlying common shares until he leaves the Board of Directors. After this award, his reported direct holdings total 25,056 shares or share-equivalent units.